2026 Annual Report & Appendix 4E

Key points

• Income from ordinary activities increased by 278.98% to $629,398
• Loss from ordinary activities after tax decreased by 154.30% to $(4,693,164)
• Net tangible assets per ordinary share decreased to 1.26 cents
• Successful technology transfer and clinical trial planning for StemSmart
• Strategic review and decision to out-license EmtinB

Full summary

NeuroScientific Biopharmaceuticals Ltd's 2026 Annual Report reveals a notable 278.98% rise in income from ordinary activities to $629,398, despite a 154.30% decrease in loss from ordinary activities after tax to $(4,693,164). The company's net tangible assets per ordinary share dropped to 1.26 cents. The Group made strides in transferring the StemSmart technology manufacturing process and initiated planning for Phase 2 clinical trials in treatment-resistant Crohn's disease. Additionally, a strategic review led to the decision to out-license EmtinB, focusing resources on StemSmart. The financial position remains robust, with a working capital surplus of $4,461,986, including cash and term deposits of $4,629,924.